Swings and roundabouts of VBP
This article was originally published in Scrip
It looks as though drugs that get patients back to work quicker and those that tackle diseases affecting younger patients' quality of life could be winners under the UK's value-based pricing system. With just three months until VBP is supposed to be up and running, details have so far been elusive, but options of how the scheme may work are now being laid on the table.
You may also be interested in...
Including the impact on hospitalizations in the label for Novartis's heart failure drug Entresto was critical to enable execution of outcome-based agreements. Such deals present an opportunity for pharma and payers to work together, but many challenges remain.
Despite the challenges with the implementation of managed entry agreements, the debate involving these complex market access routes is not abating. Speakers at the International Society for Pharmacoeconomics and Outcomes Research Europe meeting in Milan on 7–11 November 2015 discussed current experiences with such agreements across Europe, as they are about to make a bigger showing across the Atlantic.
Four years after its introduction, Germany's early benefit assessment process continues to make waves in the industry.